Edward van Wezel

Edward currently serves on the supervisory boards of Azafaros, Escalier BioSciences, Genase Therapeutics, Scenic Biotech, Staten Biotechnology, Synaffix and TigaTx. He served on the supervisory boards of Progentix Orthobiology (acquired by Nuvasive ), Noviogendix (acquired by MDxHealth) and was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca). Edward is also on the board of Mibiton.

Edward started his career as process engineer for Chiron Inc.. He subsequently worked in product development and corporate licensing at Johnson & Johnson. Since 2000 he expanded his experience as CEO of several life sciences companies in the Netherlands.

Edward holds a M.Sc. in chemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the Delft University of Technology.